HARBIN GLORIA PHARMACEUTICALS Co., LTD (SHE:002437)

China flag China · Delayed Price · Currency is CNY
3.120
-0.080 (-2.50%)
May 20, 2026, 12:54 PM CST
Market Cap7.14B +33.5%
Revenue (ttm)2.12B -11.5%
Net Income411.58M +71.0%
EPS0.18 +74.4%
Shares Out2.23B
PE Ratio17.32
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume26,963,500
Average Volume93,161,958
Open3.130
Previous Close3.200
Day's Range3.120 - 3.190
52-Week Range2.490 - 4.080
Beta0.24
RSI36.62
Earnings DateApr 28, 2026

About SHE:002437

Harbin Gloria Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products primarily in the People's Republic of China. It offers cardiac cerebrovascular medication, skeletal muscle system, vitamins and minerals, urinary system medication, antitumor medication, endocrine medicine, anti-infective drugs, respiratory medication, antihistamine, peptic, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People's Republic of China. [Read more]

Sector Healthcare
Founded 2000
Employees 2,703
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002437
Full Company Profile

Financial Performance

In 2025, SHE:002437's revenue was 2.14 billion, a decrease of -12.51% compared to the previous year's 2.44 billion. Earnings were 376.91 million, an increase of 61.93%.

Financial Statements